
Serum Institute to conduct Brazilian trials of late-stage dengue candidate with DNDi
New Delhi: Serum Institute of India (SII), and the Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MOU) to accelerate the clinical development of a monoclonal antibody treatment for dengue. Under the collaboration, …